Evidence map›Paper›PMID 41899581›Full record

ReviewCancers2026

Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches.

Yangzhi Ou, Huaxiu Wei, Chunxiu Peng, Jin Li, Ke Wei, Chenjie Zhan, Zhiyong Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yangzhi OuState Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
Huaxiu WeiState Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
Chunxiu PengState Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
Jin LiState Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
Ke WeiState Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
Chenjie ZhanState Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
Zhiyong ZhangState Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.

Funding

the Guangxi Science and Technology Major Program AA24263028the National Natural Science Foundation of China 82073373
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

combinatorial therapyepigenetic remodelinghepatocellular carcinomaimmune checkpoint blockadeimmunosuppressionJAK–STAT3 signalingmetabolic reprogrammingmicrobiome interventionsmyeloid-derived suppressor cellstumor microenvironment

Identifiers

PMID41899581
PMCPMC13024755

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.